Indication intelligence, analysis and sector perception

Cellectis SA (CLLS) closes 9.9 M ADS offering at $2.50

February 8, 2023 7:39am

CLLS closed offering with proceeds of US$24.76 M ($22.783 M after offering expenses)

Prices its underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares (ADS), each representing the right to receive one ordinary share of Cellectis, nominal value €0.05 per share , which launched and priced on 2/2/23, at a price to the public of $2.50 per ADS.

Exercise by the underwriters, Jefferies LLC and Barclays Capital Inc., of their option to purchase an additional 1,107,800 ordinary shares of the Company to be delivered in the form of an aggregate of 1,107,800 ADSs.

Interesting: The new ordinary shares underlying the ADSs will be issued through a capital increase without shareholders' pre-emptive rights under the provisions of Article L. 225-136 of the French Commercial Code.

CLLS plans to use approximately $17.0 million (€15.6 million) of the net proceeds of the offering to fund the continued clinical development of UCART 123, UCART22, UCART20x22, and UCARTCS1.

The Bottom Line: the window is open and many are rushing to and hoping through

52-week low of $1.83 and a high of $6.06

52-week change: -46.74%

Revenue: $22.18 M

Cash: $118.18 M

Debt: $89.63 M

Book value per share: $3.00

Total cash per share: $2.61

Shares outstanding: 45.57 M

Float: 33.79 M shares

Shares short (1/13/230: 277.61 K shares

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.